CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) announced its earnings results on Monday. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.18 by $0.09, Zacks reports. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The firm had revenue of $50.92 million for the quarter, compared to analyst estimates of $35.42 million. During the same quarter last year, the firm posted $0.17 EPS.
CytomX Therapeutics Price Performance
CytomX Therapeutics stock traded up $0.95 during midday trading on Monday, hitting $1.88. 87,490,158 shares of the company were exchanged, compared to its average volume of 2,882,044. The company's fifty day moving average price is $0.66 and its 200-day moving average price is $0.85. The company has a market cap of $151.41 million, a PE ratio of 10.74 and a beta of 1.11. CytomX Therapeutics has a fifty-two week low of $0.40 and a fifty-two week high of $2.18.
Wall Street Analysts Forecast Growth
A number of brokerages recently commented on CTMX. Wedbush restated an "outperform" rating and set a $5.00 target price on shares of CytomX Therapeutics in a report on Friday, March 7th. HC Wainwright restated a "neutral" rating on shares of CytomX Therapeutics in a research report on Friday, March 7th. Piper Sandler assumed coverage on CytomX Therapeutics in a research note on Monday, April 14th. They set an "overweight" rating and a $2.50 price objective on the stock. Finally, StockNews.com began coverage on CytomX Therapeutics in a report on Tuesday, April 15th. They set a "hold" rating for the company.
Check Out Our Latest Research Report on CytomX Therapeutics
CytomX Therapeutics Company Profile
(
Get Free Report)
CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.
Further Reading
Before you consider CytomX Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytomX Therapeutics wasn't on the list.
While CytomX Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
